Abstract: The present disclosure provides interferon receptor agonists with improved safety profiles and therapeutic indices. The interferon receptor agonists are attenuated through masking and/or reduced receptor binding as compared to a wild-type interferon. IFN receptor agonists optionally further comprise a targeting moiety, e.g., a targeting moiety that recognizes a tumor- or immune cell-associated antigen and directs the interferon receptor agonist to a tumor site and/or tumor-reactive immune cells. The disclosure further provides pharmaceutical compositions comprising the interferon receptor agonists, and methods of use of the interferon receptor agonists in therapy, as well as nucleic acids encoding the interferon receptor agonists, recombinant cells that express the interferon receptor agonists and methods of producing the interferon receptor agonists.

Abstract: A crossbow de-cocking mechanism may include a trigger mechanism, a trigger latch mechanism and a winch assembly. A first rotational input to the winch may move a trigger latch to disengage the trigger mechanism. A second rotational input to the trigger latch, opposite to the first, may move the trigger mechanism to move a crossbow bowstring from a cocked position to an un-cocked position.

Abstract: CD38 is expressed on malignant plasma cells. CD28 is a costimulatory molecule required for T-cell activation and survival. Provided herein are novel anti-CD38 antibodies, anti-CD28 antibodies, and bispecific antibodies (bsAbs) that bind to both CD38 and CD28 and act as costimulatory agents to activate T cells via binding CD80 and/or CD86. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing CD38. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced CD38-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of various cancers, including multiple myeloma, lymphoma, and leukemia.

Abstract: Geolocating one or more emitters includes obtaining a set of lines of bearing (LOBs) indicative of location(s) of emitter(s), determining intersections of LOBs of the set and generating clusters informed by those intersections, assigning the LOBs of the set to cluster(s) based on proximity, identifying a cluster having the greatest number of assigned LOBs from the set; determining an emitter location area based on a best point estimate for the cluster, and indicating a location of an emitter as the emitter location area. Additional emitters can be located by removing from the set of LOBs those LOBs assigned to the identified cluster, and repeating aforementioned aspects. Initially, the set of LOBs can be selected from a larger collection as a representative subset thereof.

Abstract: Systems, methods, and computer-readable storage devices to enable secured data access from a mobile device executing a native mobile application and a headless browser are disclosed.

Abstract: A firearm bore cleaner for cleaning a bore of a firearm includes a cleaning segment and a pulling segment. The cleaning segment cleans the bore of the firearm when the cleaning segment is moved along the bore. The cleaning segment includes a tail end connector adjacent a tail end portion. The pulling segment is sized and shaped to be inserted into the bore. The pulling segment includes a head end connector adjacent the head end portion of the pulling segment. A tail end portion of the pulling segment is connected to a head end portion of the cleaning segment. The head end connector of the pulling segment and the tail end connector of the cleaning segment can be releasably connect to each other to couple the head end portion of the pulling segment and the tail end portion of the cleaning segment together in order to form a closed loop.

Abstract: A modular transportation system including a transportation module with loading features, and methods of use. The transportation module comprising: a frame member having a front and a rear opposing ends, wherein the front end comprising an overhang member having an overhang portion protruding downwardly below the frame member; the overhang portion having at least one approach wheel; a base member comprising a plurality of ground wheels; a lifting assembly connected between the base member and the frame member; the lifting assembly configured to lift and lower the frame member relative to the base member; and a leg member comprising a leg body and at least one loading wheel; the leg body having a first end and a second end; the first end connected to the frame member; and the loading wheel connected to the second end. A cart and work cells reconfigure the system for specialty purposes.

Abstract: Nucleic acid-guided nuclease editing in mammalian cells may include passaging mammalian cells, in an automated closed cell editing instrument, into smaller aggregates when the aggregates exceed 50-300 microns in size. A library of viral particles may be delivered to the mammalian cells at a multiplicity of infection such that each mammalian cell receives one or no viral particle. The library may include viral vectors with an editing cassette including a pair of gRNA coding sequence and donor DNA. Conditions may be provided to allow a viral vector of the viral vectors to integrate into the mammalian cells. Enriching for mammalian cells may be done with an integrated viral vector. A nucleic acid-guided nuclease or nuclease fusion or a coding sequence for a nucleic acid-guided nuclease or nuclease fusion may be delivered to the enriched mammalian cells and conditions may be provided to allow editing in the mammalian cells.

Abstract: The present disclosure provides IL2 proproteins comprising an IL2 moiety that is masked with an IL2R? moiety and a protease-cleavable linker, configured such that the IL2R? moiety is released from the IL2 moiety upon the action of a protease, e.g., at a tumor site. The IL2 proproteins optionally further comprise a targeting moiety, e.g., a targeting moiety that recognizes a tumor-associated antigen and directs the proprotein to a tumor site. The disclosure further provides pharmaceutical compositions comprising the IL2 proproteins, and methods of use of the IL2 proproteins in therapy, as well as nucleic acids encoding the IL2 proproteins, recombinant cells that express the IL2 proproteins and methods of producing the IL2 proproteins.

Abstract: Technology is described for providing automated access to a property. The method can include identifying an access request at an access agent. The access request can define a physical visit by a service provider during a defined time period at a property. An approval from a property representative may be received to create a scheduled visit in response to the access request. Another operation is receiving a notification from a device in communication with the access agent that a person is detected at the property at a scheduled visit time and location. The identity of the person may be authenticated as being the service provider using an authentication agent. An automation device under control of the access agent may be activated to enable physical access to property for the service provider.

Abstract: The present disclosure provides IL2 proproteins comprising an IL2 moiety that is masked with an IL2R? moiety and a protease-cleavable linker, configured such that the IL2R? moiety is released from the IL2 moiety upon the action of a protease, e.g., at a tumor site. The IL2 proproteins optionally further comprise a targeting moiety, e.g., a targeting moiety that recognizes a tumor-associated antigen and directs the proprotein to a tumor site. The disclosure further provides pharmaceutical compositions comprising the IL2 proproteins, and methods of use of the IL2 proproteins in therapy, as well as nucleic acids encoding the IL2 proproteins, recombinant cells that express the IL2 proproteins and methods of producing the IL2 proproteins.

Abstract: The present invention provides methods of treating, ameliorating, or inhibiting tumor growth, cancer, or pathological angiogenesis by administering to a subject in need thereof a human antibody or fragment thereof that specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The anti-hDll4 antibody or fragment thereof of the present invention have a high affinity with the KD of 500 pM or less, as measured by surface plasmon resonance.

Abstract: A firearm bore cleaner for cleaning a bore of a firearm includes a cleaning segment and a pulling segment. The cleaning segment cleans the bore of the firearm when the cleaning segment is moved along the bore. The cleaning segment includes a tail end connector adjacent a tail end portion. The pulling segment is sized and shaped to be inserted into the bore. The pulling segment includes a head end connector adjacent the head end portion of the pulling segment. A tail end portion of the pulling segment is connected to a head end portion of the cleaning segment. The head end connector of the pulling segment and the tail end connector of the cleaning segment can be releasably connect to each other to couple the head end portion of the pulling segment and the tail end portion of the cleaning segment together in order to form a closed loop.

Abstract: Provided herein are methods of mediating killing of a tumor cell by administering to the subject a multispecific antigen binding molecule with a first antigen binding region specific for first target antigen and a second antigen binding region specific for a CD28 protein. In some embodiments, the tumor cell does not express the target antigen. In some embodiments, the tumor cell is not predicted to express the target antigen.

Abstract: Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.

Abstract: Systems, methods, and computer-readable storage devices that enable secured data access from a mobile device executing a native mobile application and a headless browser. The technology includes interactions between an API, a secure connection, a headless browser, that utilize one or more of web site data, fingerprint data file locations and additional web page data.

Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.

Abstract: The present disclosure relates to IL2 agonists with improved therapeutic profiles.

Abstract: A method of grinding large sample quantities using a bead beater homogenizer includes steps of loading a sample material into a vial having a size of 500 ml or greater having a chamber enclosed by two end walls and a cylindrical sidewall defining a central vial axis, loading a plurality of balls into the vial with the sample material, securing the vial to a movable platform of the homogenizer, and oscillating the platform in a back-and-forth motion isolated to a movement axis, thereby causing the balls to move in a circular motion along the cylindrical sidewall, wherein the central vial axis is perpendicular to the movement axis. A system of a cylindrical vial and a bead beater homogenizer is also provided.

Abstract: The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen-binding molecule that specifically binds human PSMA. In certain embodiments, the bispecific antigen- binding molecules of the present invention are capable of inhibiting the growth of tumors expressing PSMA, such as prostate tumors. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an up-regulated or induced targeted immune response is desired and/or therapeutically beneficial.